Company news

Formosa Pharmaceuticals, Inc. news in 2024

Formosa Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain

November 29, 2024

Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain after Cataract Surgery

November 5, 2024

Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization

September 9, 2024

Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

August 6, 2024

Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals

May 10, 2024

Decks in 2024